Analysts Set Expectations for KROS Q4 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at Wedbush issued their Q4 2025 earnings per share estimates for Keros Therapeutics in a report released on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will earn ($1.27) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share.

A number of other research analysts also recently commented on the company. Guggenheim began coverage on Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective for the company. Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a research note on Tuesday. They set a “buy” rating for the company. Scotiabank assumed coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on Keros Therapeutics in a report on Thursday, October 24th. They set an “overweight” rating on the stock. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.11.

Keros Therapeutics Stock Up 4.4 %

Shares of NASDAQ:KROS opened at $62.58 on Wednesday. The company has a market cap of $2.35 billion, a PE ratio of -12.20 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The firm has a 50-day simple moving average of $56.87 and a 200 day simple moving average of $51.89.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.02). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.04 million for the quarter. During the same period last year, the firm posted ($1.27) EPS.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 22.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the third quarter worth approximately $89,000. Ameritas Investment Partners Inc. raised its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics in the 2nd quarter valued at approximately $128,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Keros Therapeutics in the third quarter worth $216,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.